Novartis Investigative Site
Jinan 250012
1 studies enrolling now · 13 studies all time
What they study most
Acute Heart Failure, Atherosclerotic Cardiovascular Disease, Autoimmunity, Inflammation, Chronic Heart Failure, Chronic Inducible Urticaria, Generalized Myasthenia Gravis, Heart Failure With Preserved Ejection Fraction, Hidradenitis Suppurativa, Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes, Ovarian Cancer, Primary Immune Thrombocytopenia
Studies at this site
- Secukinumab Open Label Roll-over Extension Protocol — Recruiting now
- A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Recruiting now
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids — Running, not enrolling
- A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines — Running, not enrolling
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected — Stopped early
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) — Running, not enrolling
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies — Running, not enrolling
- Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) — Stopped early
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study — Completed
- Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
- Global Non-interventional Heart Failure Disease Registry — Stopped early
- Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed